Today: 19 May 2026
Browse Category

Share Buyback 30 October 2025 - 10 December 2025

Singtel (SGX: Z74) Stock on 10 December 2025: Price, Dividend Payout, Buyback Firepower and 2026 Outlook

Singtel (SGX: Z74) Stock on 10 December 2025: Price, Dividend Payout, Buyback Firepower and 2026 Outlook

Singtel shares traded near record highs at S$4.58 on December 10, after a year-long rally of about 50–55%. The company posted a 14% rise in underlying net profit to S$1.35 billion for H1 FY26 and raised full-year guidance. Its Australian unit Optus faces fallout from network failures and a record court fine. Singtel’s dividend yield is close to 4%.
10 December 2025
···
Infosys Share Price Today, 8 December 2025: Q2 FY26 Results, ₹18,000-Crore Buyback and Analyst Targets for INFY Stock

Infosys Share Price Today, 8 December 2025: Q2 FY26 Results, ₹18,000-Crore Buyback and Analyst Targets for INFY Stock

Infosys closed at ₹1,616.2 on the NSE and $18.07 for its US ADR on December 8, 2025, following strong Q2 FY26 earnings and an ₹18,000-crore buyback. The stock has returned 11.9% over three months, outperforming the Nifty 50, but remains 19% below its 52-week high. Trading volumes surged, and Infosys trades at a P/E of 23.98x, below the sector average.
8 December 2025
·····
Zoom Communications Inc (ZM) Stock: AI‑Powered Rebound, Buyback Momentum and Wall Street Forecasts as of December 6, 2025

Zoom Communications Inc (ZM) Stock: AI‑Powered Rebound, Buyback Momentum and Wall Street Forecasts as of December 6, 2025

Zoom stock closed at $87.65 on December 6, 2025, up 1.24% for the day, with a market cap near $25.9 billion. Fiscal Q3 2026 results beat estimates, posting $1.23 billion in revenue and $1.52 adjusted EPS. The company raised its annual outlook, citing strong AI demand and authorized a $1 billion share buyback. Shares remain down nearly 79% from 2020 highs.
7 December 2025
···
Infosys Share Price Today: Buyback 2025, GST Demand, Q2 FY26 Results and Stock Forecast Explained

Infosys Share Price Today: Buyback 2025, GST Demand, Q2 FY26 Results and Stock Forecast Explained

Infosys closed its ₹18,000 crore share buyback, with shares trading near ₹1,565 on 2 December, little changed from the previous close. Intraday movement stayed within ₹1,562–₹1,579. The stock has gained about 1% over the past week and 5–6% in a month, but remains down 16–17% over the past year. Trailing P/E stands at 23x, with a market cap near ₹6.5 lakh crore.
2 December 2025
····
Mercedes‑Benz Group AG Stock on 1 December 2025: AI Push, €2 Billion Buyback and a 7%+ Dividend Put MBG.DE in Focus

Mercedes‑Benz Group AG Stock on 1 December 2025: AI Push, €2 Billion Buyback and a 7%+ Dividend Put MBG.DE in Focus

Mercedes-Benz shares traded near €58.38 on Xetra early 1 December, up 0.4% for the session and about 10% year-to-date. The company announced a board reshuffle, a new goal for half its workforce to use AI by end-2025, and continued a €2 billion share buyback, but kept its 2025 earnings outlook downbeat.
1 December 2025
····
Siemens Aktiengesellschaft (SIE.DE) Stock Today, 27 November 2025: Sideways Trade, 350,000‑Share Buyback and a New Rail Deal in Chile

Siemens Aktiengesellschaft (SIE.DE) Stock Today, 27 November 2025: Sideways Trade, 350,000‑Share Buyback and a New Rail Deal in Chile

Siemens shares traded at €227.50 on Tradegate at 12:30 CET Thursday, down 0.24%, after the company reported repurchasing 350,762 shares last week. The stock remains about 26% higher year-on-year, near its 52-week high, following record fiscal results and a major rail contract win in Chile. Analyst targets were trimmed but still rate the stock a “Buy.”
27 November 2025
··
Barclays PLC Share Price Today: Buyback Momentum, £500m Bond Redemption and Ubisoft Stake Drive 400p Rally (24 November 2025)

Barclays PLC Share Price Today: Buyback Momentum, £500m Bond Redemption and Ubisoft Stake Drive 400p Rally (24 November 2025)

Barclays closed at about 398.5p in London on 24 November, up 1.5% after confirming the cancellation of 4.08 million shares as part of its ongoing £1bn buyback. The bank’s stock has climbed nearly 50% in the past year and now trades close to its tangible net asset value. Market capitalization stands near £56 billion. Barclays has repurchased roughly 255 million shares since July.
24 November 2025
····
Vodafone (LSE: VOD) lifts dividend for the first time in 8 years, launches €500m buyback and targets upper‑end FY26 outlook — stock pops on 11 Nov 2025

Vodafone Share Price Today: Buyback Progress, Dividend Growth and £3bn Lawsuit – 18 November 2025 Update

Vodafone shares closed at 92p in London on 18 November, near a 52-week high and valuing the group at about £21.9bn. The company confirmed a €500m buyback program, repurchasing 1 million shares on 17 November. UK regulators allowed a £3bn class-action lawsuit against Vodafone and rivals to proceed. Vodafone Egypt reported 46% H1 growth; Vodafone Idea in India narrowed losses.
18 November 2025
···
Ambev’s Profit Soars 36% in Q3 – Buyback Announced as ABEV Stock Eyes Rally

Ambev’s Profit Soars 36% in Q3 – Buyback Announced as ABEV Stock Eyes Rally

Ambev S.A. reported Q3 net income of 4.86 billion reais, up 36% year-on-year and well above analyst forecasts. Beer volumes fell 5.9%, but higher prices kept revenue flat; EBITDA was R$7.06 billion, beating estimates. The board approved a buyback of up to 208 million shares. Shares traded around $2.25 after results, with analysts split on outlook amid sector headwinds.
30 October 2025
··
1 2

Stock Market Today

  • FTSE 100 Rises as UK Jobs Market Cools and Trump Cancels Iran Strikes
    May 19, 2026, 2:37 AM EDT. The FTSE 100 was called higher on Tuesday following UK labour market data that showed cooling signs, with unemployment rising to 5.0% and payrolled employment declining sharply by 100,000, far exceeding expectations. Wages excluding bonuses rose 3.4%, in line with forecasts. U.S. President Donald Trump called off planned strikes against Iran, easing geopolitical tensions. The London blue-chip index was poised to gain around 35 points. U.S. markets were mixed, with Nasdaq down 0.5% and Dow Jones up 0.3%. Asian markets fluctuated, with gains in Hong Kong and Shanghai but losses in Japan. Investors remain cautious about the Bank of England's next move on interest rates amid these mixed economic signals.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Go toTop